Dexrazoxane has been used to protect the [[heart]] against the [[cardiotoxic]] side effects of chemotherapeutic drugs such as [[anthracycline]]s,<ref name="pmid15247354">{{cite journal |doi=10.1056/NEJMoa035153 |title=The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia |year=2004 |last1=Lipshultz |first1=Steven E. |last2=Rifai |first2=Nader |last3=Dalton |first3=Virginia M. |last4=Levy |first4=Donna E. |last5=Silverman |first5=Lewis B. |last6=Lipsitz |first6=Stuart R. |last7=Colan |first7=Steven D. |last8=Asselin |first8=Barbara L. |last9=Barr |first9=Ronald D. |last10=Clavell |first10=Luis A. |last11=Hurwitz |first11=Craig A. |last12=Moghrabi |first12=Albert |last13=Samson |first13=Yvan |last14=Schorin |first14=Marshall A. |last15=Gelber |first15=Richard D. |last16=Sallan |first16=Stephen E. |journal=New England Journal of Medicine |volume=351 |issue=2 |pages=145–53 |pmid=15247354|display-authors=8 }}</ref> such as [[daunorubicin]] or [[doxorubicin]] or other chemotherapeutic agents.<ref name="pmid18040065">{{cite journal |doi=10.3181/0705-RM-138 |title=Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy in Vivo |year=2007 |last1=Bjelogrlic |first1=Snezana K. |last2=Radic |first2=Jelena |last3=Radulovic |first3=Sinisa |last4=Jokanovic |first4=Milan |last5=Jovic |first5=Viktor |journal=Experimental Biology and Medicine |volume=232 |issue=11 |pages=1414–24 |pmid=18040065}}</ref> However, in July 2011 the US Food and Drug Administration released a statement restricting use only in adult patients with cancer who have received > 300&nbsp;mg/m2 doxorubicin (an anthracycline) or > 540&nbsp;mg/m2 epirubicin (another chemotherapeutic agent) and general approval for use for cardioprotection.<ref>Tebbi CK, et al. J Clin Oncol 2007; 25: 493–500</ref><ref>Salzer WL, et al. Leukemia 2010; 24: 355–70</ref> That showed a possibly higher rate of secondary malignancies and acute myelogenous leukemia in pediatric patients treated for different cancers with both dexrazoxane and other chemotherapeutic agents that are associated with secondary malignancies.<ref>{{cite web|url= http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm|title= FDA Statement on Dexrazoxane}}</ref>
